Stocks and InvestingStocks and Investing
Tue, March 1, 2022
Mon, February 28, 2022
Sun, February 27, 2022
Fri, February 25, 2022

Matt Borsch Upgraded (AMED) to Buy and Held Target at $190 on, Feb 25th, 2022


Published on 2024-10-27 19:50:01 - WOPRAI, Matt Borsch
  Print publication without navigation


Matt Borsch of BMO Capital, Upgraded "Amedisys, Inc." (AMED) to Buy and Held Target at $190 on, Feb 25th, 2022.

Matt has made no other calls on AMED in the last 4 months.



There are 7 other peers that have a rating on AMED. Out of the 7 peers that are also analyzing AMED, 2 agree with Matt's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Whit Mayo of "SVB Leerink" Maintained at Hold with Increased Target to $147 on, Friday, February 18th, 2022
  • Scott Fidel of "Stephens & Co." Maintained at Hold with Increased Target to $185 on, Thursday, November 4th, 2021


These are the ratings of the 5 analyists that currently disagree with Matt


  • Bill Sutherland of "Benchmark" Maintained at Strong Buy with Decreased Target to $175 on, Thursday, February 24th, 2022
  • Steve Valiquette of "Barclays" Maintained at Buy with Decreased Target to $213 on, Tuesday, December 21st, 2021
  • John Ransom of "Raymond James" Maintained at Buy with Decreased Target to $225 on, Monday, November 8th, 2021
  • Jonathan Yong of "Credit Suisse" Maintained at Buy with Increased Target to $205 on, Thursday, November 4th, 2021
  • Frank Morgan of "RBC Capital" Maintained at Buy with Decreased Target to $221 on, Thursday, November 4th, 2021